Drugs / Sumatriptan
Sumatriptan
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZEMBRACE SYMTOUCH | — | 2019-06-10 | fda.gov ↗ |
| Label expansion | US (FDA) | SUMAVEL DOSEPRO | — | 2013-11-26 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Sumatriptan Galpharm | — | 2012-02-09 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | IMITREX STATDOSE | — | 1996-05-22 – 2006-02-01 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | IMITREX | — | 1998-02-13 – 2004-10-13 | fda.gov ↗ |
| Approved | US (FDA) | IMITREX STATDOSE | — | 1992-12-28 | fda.gov ↗ |
Trials 60
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04690270 | Jan → Jun 2021 | obesity disorder | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 120 trials · 1 met primary | ||||||
| Phase 1 | NCT05064488 | Oct → Dec 2021 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT04355845 | Jun → Aug 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04197349 | Sep 2019 → Aug 2020 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT03310411 | Oct → Dec 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03076970 | Mar → Apr 2017 | migraine disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02932488 | Sep 2016 → Jun 2019 | — | Gitte Moos Knudsen | Terminated | No outcome recorded |
| Phase 1 | NCT02954276 | Mar → Aug 2016 | migraine disorder | Targia Pharmaceuticals Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02741310 | Feb → Aug 2016 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02684409 | Aug 2013 → Nov 2014 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02054299 | Apr 2013 → Feb 2016 | — | University Medical Center Goettingen | Completed | No outcome recorded |
| Phase 1 | NCT01579383 | Apr → Dec 2012 | migraine disorder | Alder Biopharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01507610 | Jan → Feb 2012 | migraine disorder | Optinose US Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01381796 | Dec 2009 → Sep 2010 | — | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00723983 | Nov 2008 → Sep 2009 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00720018 | Jun → Jul 2008 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00620425 | Dec 2007 | — | Zogenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00701389 | Nov 2007 → Apr 2008 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00648466 | Nov → Dec 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00650247 | Nov 2004 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00847405 | Mar 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 25 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT03877718 | Feb → Aug 2019 | migraine disorder | Charleston Laboratories, Inc | Completed | No outcome recorded |
| Phase 2 | NCT02856802 | Jul 2016 → Feb 2017 | migraine disorder | Upsher-Smith Laboratories | Completed | Met primary |
| Phase 2 | NCT02571049 | Sep 2015 → Apr 2016 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | Missed primary |
| Phase 2 | NCT01854385 | Jun 2013 → Feb 2018 | — | University of Washington | Completed | Missed primary |
| Phase 2 | NCT01791400 | Jul 2009 → Nov 2010 | migraine disorder | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01016678 | Mar 2010 → Jun 2014 | migraine disorder | Premiere Research Institute | Completed | Mixed |
| Phase 323 trials · 8 met primary · 1 missed | ||||||
| Phase 3 | NCT04948164 | Aug 2018 → Dec 2021 | migraine disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03338920 | Nov 2017 → Apr 2022 | migraine disorder | Currax Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02569853 | Sep 2015 → May 2017 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | Met primary |
| Phase 3 | NCT02279082 | Sep 2014 → Sep 2015 | migraine disorder | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 3 | NCT00806546 | Feb 2009 → May 2011 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00792103 | Jan 2009 → Sep 2010 | migraine disorder | NuPathe Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00724815 | Jan → Jul 2009 | migraine disorder | NuPathe Inc. | Completed | Met primary |
| Phase 3 | NCT00843024 | Dec 2008 → May 2010 | migraine disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00573170 | Feb 2008 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00488514 | Jul 2007 → Aug 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00510419 | Jul → Dec 2007 | migraine disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00382993 | Dec 2006 → Nov 2007 | migraine disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00383162 | Nov 2006 → Oct 2007 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00385008 | Sep → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00387881 | Sep 2006 → Feb 2008 | migraine without aura | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00356603 | Jun → Aug 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00329355 | May → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00329459 | May → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00433732 | Aug 2004 → Apr 2005 | migraine disorder | POZEN | Completed | Mixed |
| Phase 3 | NCT00434083 | Jul 2004 → Jan 2005 | migraine disorder | POZEN | Completed | Met primary |
| Phase 3 | NCT01986270 | Dec 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01986088 | Nov 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00897104 | Aug 1995 → May 1996 | migraine disorder | Organon and Co | Completed | No outcome recorded |
| Phase 46 trials · 2 met primary | ||||||
| Phase 4 | NCT01807234 | Feb 2013 → Dec 2014 | migraine disorder | Johns Hopkins University | Completed | Met primary |
| Phase 4 | NCT01071317 | Feb 2010 → Jan 2012 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01016834 | Nov 2009 → Apr 2010 | migraine disorder | Zogenix, Inc. | Completed | Met primary |
| Phase 4 | NCT00893737 | Jun 2009 → Jan 2010 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00792636 | Nov 2008 → Nov 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00399243 | Nov 2006 → Aug 2010 | cluster headache syndrome | Diamond Headache Clinic | Unknown | No outcome recorded |
| Phase not applicable4 trials · 1 met primary | ||||||
| — | NCT07515456 | Dec 2024 → Nov 2026 expected | intracranial hypotension | Tanta University | Recruiting | No outcome recorded |
| — | NCT05654298 | Mar 2022 → Mar 2023 | migraine disorder | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01632657 | Jun 2012 → Oct 2019 | — | University Health Network, Toronto | Completed | Met primary |
| — | NCT00399633 | Jan → Apr 2007 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| Comparator or background therapy49 trials | ||||||
| Phase 1 | NCT03229798 Comparator | Jan → Mar 2018 | migraine disorder | Sorrento Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00989625 Comparator | Nov 2008 → Sep 2009 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00875784 Comparator | May → Jun 2008 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00546650 Comparator | Nov → Dec 2007 | — | NuPathe Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00846885 Comparator | Aug → Sep 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 2 | NCT02176655 Comparator | Jul 2014 → Jan 2016 | alcohol-induced mental disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT01430442 Comparator | Oct 2011 → May 2012 | migraine disorder | Pfizer | Completed | Met primary |
| Phase 2 | NCT00920686 Comparator | Jun 2009 → Mar 2010 | migraine with aura | NeurAxon Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00892203 Comparator | Apr 2009 → Aug 2010 | migraine disorder | Novartis | Completed | Missed primary |
| Phase 2 | NCT00804973 Comparator | Nov 2008 → May 2009 | migraine disorder | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 2/3 | NCT03185143 Comparator | Jun 2017 → May 2018 | migraine disorder | Allodynic Therapeutics, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01814189 Comparator | Jan → Apr 2013 | migraine with aura, migraine without aura | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01667679 Comparator | Aug 2012 → Mar 2014 | migraine disorder | Avanir Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01462812 Comparator | Jan 2011 → Jun 2012 | migraine disorder | Optinose US Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00963937 Comparator | Sep 2009 → Dec 2010 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00894556 Background | Jun 2009 → Jan 2010 | migraine disorder | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00240617 Comparator | Oct 2005 → Jun 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00240630 Comparator | Oct 2005 → Jun 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00442221 Background | May → Aug 2004 | migraine disorder | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00898677 Comparator | Sep 1995 → May 1996 | migraine disorder | Organon and Co | Completed | Met primary |
| Phase 4 | NCT07022496 Background | Apr 2023 → Jul 2025 overdue | migraine disorder | Ain Shams University | Recruiting | No outcome recorded |
| Phase 4 | NCT05108688 Comparator | Nov 2021 → Dec 2023 | headache disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04257851 Comparator | Feb 2020 → May 2021 | intracranial hypotension | Damanhour Teaching Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01329562 Comparator | May 2011 → Jun 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01300546 Comparator | Dec 2010 → Apr 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01248468 Comparator | Nov 2010 → Mar 2011 | migraine disorder | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01090050 Comparator | Sep 2010 → Jun 2012 | migraine disorder | Cady, Roger, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01053507 Comparator | May 2010 → Nov 2012 | traumatic encephalopathy | Cady, Roger, M.D. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01450995 Comparator | Dec 2009 → May 2011 | migraine disorder | Stephen H. Landy, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01086358 Comparator | Sep 2009 → Aug 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01138150 Comparator | Sep 2009 → Jun 2013 | migraine disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT01476930 Comparator | Jun 2008 → Sep 2009 | migraine disorder | Birjand University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00449787 Comparator | Mar 2007 → Jul 2009 | migraine disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00910689 Comparator | Jul 2001 → Nov 2005 | migraine disorder | Ohio University | Completed | No outcome recorded |
| — | NCT06617832 Comparator | Nov 2024 → Sep 2028 expected | migraine with aura, migraine without aura | University of Aarhus | Recruiting | No outcome recorded |
| — | NCT06514040 Comparator | Nov 2023 → Aug 2024 | intracranial hypotension | Fayoum University Hospital | Completed | No outcome recorded |
| — | NCT05211050 Comparator | Mar 2022 → Nov 2023 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03878784 Comparator | Nov 2018 → Dec 2019 | rosacea | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03881644 Comparator | Jul 2018 → Dec 2019 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03542357 Comparator | Feb → Sep 2018 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03422796 Comparator | Nov 2017 → Sep 2018 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT03156920 Comparator | May → Oct 2017 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT02643719 Comparator | Dec 2015 → Oct 2017 | migraine disorder | NYU Langone Health | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02486276 Comparator | Jun 2015 → Jun 2016 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT02485340 Comparator | Apr → Aug 2015 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT00893594 Comparator | Oct 2010 → Dec 2015 | migraine with aura | Dent Neurologic Institute | Unknown | No outcome recorded |
| — | NCT00837044 Comparator | Feb → Jul 2009 | cognitive disorder, migraine disorder | Neurological Research Center | Unknown | No outcome recorded |
| — | NCT00573599 Comparator | Feb → May 2007 | migraine disorder | United States Naval Medical Center, Portsmouth | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-11-01 | Alembic Pharmaceuticals Ltd. | Regulatory 07th November, 2025 Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System. |
| 2011-06-21 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA approval for generic Imitrex® injection sunpharma.com ↗
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sumatriptan Succinate Injection, 6 mg (base) / 0.5mL. |
| 2009-08-11 | Sun Pharmaceutical Industries, Inc. | Regulatory Generic Eloxatin® and Imitrex® approval: shares 180-day marketing drug exclusivity for generic Eloxatin® sunpharma.com ↗ |
| 2009-02-17 | Wockhardt | Regulatory Wockhardt to launch generic version of migraine drug Sumatriptan in the US market wockhardt.com ↗
Wockhardt received the final appr oval from the United States Food & Drug Administration (US FDA) for marketing the injections containing 6mg per 0.5ml Sumatriptan succinate, which is used for treating migraine headaches. |
| 2009-02-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval and Launch of Generic Imitrex® Tablets tevapharm.com ↗
the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of GlaxoSmithKline's Imitrex® Tablets, 25 mg, 50 mg and 100 mg |
| 2006-11-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval Of Sumatriptan Succinate Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Sumatriptan Succinate Tablets, 25 mg, 50 mg and 100 mg. |
All press releases naming this drug 13 releases
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 112 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sumatriptan | “This randomized, open-label, 3-period crossover study compared the exposure to sumatriptan (Cmax and AUC to 14 hours after the administration of the second dose [AUC(0-14)])...” PMID 20637969 ↗ Jun 2010100“The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or...” NCT00910689 ↗ “Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗ “One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.” NCT01138150 ↗ “BACKGROUND: DFN-11, a 3 mg sumatriptan subcutaneous (SC) autoinjector for acute treatment of migraine, has not been assessed previously in multiple attacks.” PMID 30112725 ↗ Aug 2018 “One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.” NCT02176655 ↗ “Treximet(tm) is a triptan tablet containing a combination of sumatriptan 85mg (Imitrex) and naproxen sodium 500 mg.” NCT01450995 ↗ “ComboProduct Containing Sumatriptan and Naproxen Sodium for Acute Treatment of Migraine in Adolescents” NCT01016678 ↗ “NP101, a transdermal sumatriptan formulation in development for the acute treatment of migraine” PMID 22352764 ↗ Feb 2012 “with sumatriptan-naproxen (Treximet®) or placebo in a double-blind, placebo-controlled fashion” PMID 23406052 ↗ Feb 2013 “Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine” NCT06617832 ↗ |
| Known as | Alsuma() | “a novel sumatriptan auto-injector (Alsuma(®)), and to evaluate the safety, tolerability, and effectiveness of this sumatriptan auto-injector during an acute migraine attack.” PMID 23148799 ↗ Nov 2012 |
| Known as | DFN-02 | “A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.” NCT02856802 ↗ |
| Known as | DFN-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02569853 ↗ |
| Known as | Imigran | “Sumatriptan (Imigran) is a selective serotonin receptor agonist. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and...” NCT06514040 ↗ |
| Known as | Imitrex | “the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal...” NCT02954276 ↗8“This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of...” NCT03076970 ↗ “IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®” NCT00875784 ↗ “20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray” NCT01507610 ↗ “100 mg oral tablet commercial Imitrex sumatriptan succinate tablet” NCT03229798 ↗ “Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.” NCT00546650 ↗ |
| Known as | NP101 | “A Phase I, Open Label, Single-Dose, Four-Way Crossover Study Comparing the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of...” NCT00723983 ↗6“Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗ “A Phase I, Single Center, Open Label, Single-Dose, Five-Period Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) in Healthy Volunteers” NCT00720018 ↗ “OBJECTIVE: To assess the long-term tolerability and efficacy of NP101, a novel transdermal sumatriptan patch being developed for the acute treatment of migraine.” PMID 22352764 ↗ Feb 2012 “Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex” NCT01381796 ↗ “NP101 (Sumatriptan Iontophoretic Transdermal Patch)” NCT00546650 ↗ “NP101 - sumatriptan iontophoretic transdermal patch” NCT00724815 ↗ |
| Known as | Omexa | “the trial is a randomized, open label, crossover, single-administration bioavailability study to compare the pharmacokinetic parameters of Omexa sumatriptan transmucosal...” NCT02954276 ↗ |
| Known as | OPTINOSE SUMATRIPTAN | “20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray” NCT01507610 ↗ |
| Known as | sumatriptan succinate | “Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.” NCT00806546 ↗12“Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer” NCT00383162 ↗ “fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg” NCT00573170 ↗ “IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®” NCT00875784 ↗ “One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)” NCT03877718 ↗ “Combination Product (sumatriptan succinate / naproxen sodium)” NCT00385008 ↗ “Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.” NCT00546650 ↗ “Treatment C - oral sumatriptan succinate” NCT01381796 ↗ “Sumatriptan Succinate Tablets 100 mg” NCT00648466 ↗ “sumatriptan succinate 100 mg” NCT00920686 ↗ |
| Known as | Sumigran 25 | “Patients included in this group will receive oral 25 mg sumatriptan succinate tablet (Sumigran 25, 25 mg tablet, Sigma pharmaceutical industries, Egypt) every 12 hours.” NCT07515456 ↗ |
| Action | Activate | “The receptor can be stimulated with the agonist sumatriptan” NCT02932488 ↗ |
| Route | Oral | “sumatriptan succinate/naproxen sodium) tablets vs placebo” NCT00329355 ↗ |